Risk factor
Very poor trading liquidity
Profitability factor
Greatly overvalued vs peers
About
Genetics Generation Advancement Corp. (GGAC), headquartered in Taipei, Taiwan, specializes in providing advanced genetic testing and bioinformatics solutions. The company serves a diverse global clientele across Taiwan, Asia, Europe, and the Americas. GGAC offers a comprehensive array of genetic screenings tailored for various life stages and health needs. These include pre-conception, prenatal, and newborn testing, in addition to adult health management, cancer predisposition, and pharmacogenetic analyses. The company also collaborates with and provides services to institutional partners. Beyond its core genetic services, Genetics Generation Advancement Corp. extends its expertise to encompass life sciences, materials science, sophisticated laboratory informatics, enterprise quality management systems (EQMS), Manufacturing Execution Systems (MES), and efficient electronic data delivery solutions. Originally founded in 2008 as Genesis Genetics Asia Corp., the company officially rebranded and adopted its current name, Genetics Generation Advancement Corp., in February 2016.
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. Specifically, the stock is 'expensive' on P/E, overvalued on EV/EBITDA,